New data shows UZEDY® Risperidone Reduces Emergency Care for Schizophrenia

Teva Pharmaceuticals has revealed compelling new real-world data that positions UZEDY® (risperidone) as a superior option among long-acting injectables for schizophrenia treatment. According to the study, patients treated with UZEDY® remain on their treatment plans more consistently compared to those using other long-acting injectables. The data suggests that UZEDY® not only enhances treatment adherence but also significantly reduces the need for emergency care and subsequent healthcare costs. This could be a game-changer in managing schizophrenia, a condition that demands consistent medication adherence for optimal outcomes. The findings emphasize the potential of UZEDY® to improve patient experiences and lighten the economic burden of schizophrenia on healthcare systems. As long-acting injectables gain prominence in mental health care, UZEDY® emerges as a promising option for both patients and healthcare providers.

Macau Business